Athena Strategy for Opioid Use Disorder (OUD)

Phase-Based Progress Estimates
Yale University, New Haven, CT
Opioid Use Disorder (OUD)+4 More
Athena strategy - CombinationProduct
18 - 65
What conditions do you have?

Study Summary

The purpose of this 2-site (CT, AL) study is to test innovative interventions to reduce stigma and improve the pre-exposure prophylaxis (PrEP) and opioid use disorder (OUD) care continua in women involved in the criminal justice system (WICJ). This study evaluates a newly validated PrEP decision aid and eHealth for integrated PrEP and MOUD compared to a decision aid-only for WICJ with OUD.

Eligible Conditions

  • Opioid Use Disorder (OUD)
  • Human Immunodeficiency Virus (HIV) Infections
  • eHealth

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Opioid Use Disorder (OUD)

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Month 1, Month 3, and Month 6

Month 6
Change in Opioid use disorder treatment cascade engagement
Change in PrEP Adherence
Change in PrEP initiation

Trial Safety

Safety Progress

1 of 3

Other trials for Opioid Use Disorder (OUD)

Trial Design

2 Treatment Groups

Decision Aid
1 of 2
Athena Strategy
1 of 2
Active Control
Experimental Treatment

250 Total Participants · 2 Treatment Groups

Primary Treatment: Athena Strategy · No Placebo Group · N/A

Athena Strategy
Experimental Group · 1 Intervention: Athena strategy · Intervention Types: CombinationProduct
Decision Aid
ActiveComparator Group · 1 Intervention: Decision Aid · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: month 1, month 3, and month 6
Closest Location: Yale University · New Haven, CT
Photo of Yale University New Haven  1Photo of Yale University New Haven  2Photo of Yale University New Haven  3
1992First Recorded Clinical Trial
1 TrialsResearching Opioid Use Disorder (OUD)
474 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · Female Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.